Valeant On Stronger Ground As It Readies For Allergan Showdown
This article was originally published in The Pink Sheet Daily
Executive Summary
The Canadian pharma reported a strong third quarter and an improved debt position as it prepares for the December meeting with Allergan shareholders that could result in an ousting of the Botox-maker’s board.
You may also be interested in...
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
Update: Ziopharm Study Death Not Due To Drug
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: